AI Verdict
IBTA has stronger fundamentals based on our AI analysis.
IBTA vs IBRX Fundamental Comparison
| Metric | IBTA | IBRX |
|---|---|---|
| Revenue | $342.4M | $113.3M |
| Net Income | $3.6M | $-351.4M |
| Net Margin | 1.0% | -310.2% |
| ROE | 1.2% | N/A |
| ROA | 0.7% | -70.0% |
| Current Ratio | 1.96x | 5.10x |
| Debt/Equity | 0.00x | N/A |
| EPS | $0.12 | $-0.38 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IBTA vs IBRX: Frequently Asked Questions
Is IBTA or IBRX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), IBTA has stronger fundamentals. IBTA is rated HOLD (68% confidence) while IBRX is rated STRONG SELL (92% confidence). This is not investment advice.
How does IBTA compare to IBRX fundamentally?
Ibotta, Inc. has ROE of 1.2% vs ImmunityBio, Inc.'s N/A. Net margins are 1.0% vs -310.2% respectively.
Which stock pays higher dividends, IBTA or IBRX?
IBTA has a dividend yield of N/A or no dividend while IBRX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IBTA or IBRX for long term?
For long-term investing, consider that IBTA has HOLD rating with 68% confidence, while IBRX has STRONG SELL rating with 92% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IBTA vs IBRX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IBTA vs IBRX, the AI consensus favors IBTA based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.